Apellis Pharmaceuticals (APLS) Reports Q3 Earnings: What Key Metrics Have to Say

Apellis Pharmaceuticals, Inc. (APLS) reported $196.83 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 78.3%. EPS of -$0.46 for the same period compares to -$1.17 a year ago.The reported revenue represents a surprise of -1.04% over the Zacks Consensus Estimate of $198.89 million. With the consensus EPS estimate being -$0.32, the EPS surprise was -43.75%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Apellis Pharmaceuticals performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue- Product revenue, net: $176.57 million versus the 10-analyst average estimate of $189.09 million. Revenue- Licensing and other revenue: $20.26 million versus $9.50 million estimated by 10 analysts on average. Product Revenue- EMPAVELI: $24.61 million compared to the $24.61 million average estimate based on six analysts. Product Revenue- SYFOVRE: $151.96 million versus $162.36 million estimated by six analysts on average. View all Key Company Metrics for Apellis Pharmaceuticals here>>>Shares of Apellis Pharmaceuticals have returned +4% over the past month versus the Zacks S&P 500 composite's -0.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Research Chief Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Apellis Pharmaceuticals, Inc. (APLS): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks